Christine Ballegaard1, Pil Højgaard1, Lene Dreyer2, René Cordtz1, Tanja Schjødt Jørgensen3, Marie Skougaard3, Simon Tarp3, Lars Erik Kristensen3. 1. The Parker Institute and Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, and Gentofte Hospital, Hellerup, Denmark. 2. The Parker Institute and Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, and Gentofte Hospital, Hellerup, and DANBIO Registry and Rigshospitalet, Glostrup, Denmark. 3. The Parker Institute and Copenhagen University Hospital and Bispebjerg and Frederiksberg Hospital, Hellerup, Denmark.
Abstract
OBJECTIVE: The objective of this population-based cohort study was to investigate the impact of comorbidities on disease activity, treatment response, and persistence with the first-tried tumor necrosis factor inhibitor (TNFi) in patients with psoriatic arthritis (PsA). METHODS: Data on patient characteristics, disease activity, and treatment response and persistence were obtained from the DANBIO registry. Information on comorbidities according to the Charlson Comorbidity Index (CCI) was obtained through linkage with the Danish National Patient Register. Kaplan-Meier plots and Cox proportional hazard regression analyses were performed. Percentages of patients achieving relevant clinical responses were calculated. RESULTS: We identified 1,750 patients eligible for analyses. Patients with higher CCI scores had higher disease activity measures at baseline and increased occurrence of depression and/or anxiety. Kaplan-Meier curves showed shorter persistence with treatment for patients with a CCI score ≥2 (log-rank P < 0.001) and for patients with depression and/or anxiety (P = 0.027) compared to patients without comorbidities. In multivariate analysis, a CCI score ≥2 was associated with reduced TNFi persistence compared with patients without comorbidities (hazard ratio 1.72 [95% confidence interval 1.26-2.37]; P = 0.001). A smaller proportion of patients with a CCI score ≥2 achieved European League Against Rheumatism (EULAR) good response (P < 0.001) and EULAR good-or-moderate response (P < 0.001) at 6 months compared with patients without comorbidities. CONCLUSION: The presence of comorbidities was associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates in a cohort of Danish patients with PsA.
OBJECTIVE: The objective of this population-based cohort study was to investigate the impact of comorbidities on disease activity, treatment response, and persistence with the first-tried tumor necrosis factor inhibitor (TNFi) in patients with psoriatic arthritis (PsA). METHODS: Data on patient characteristics, disease activity, and treatment response and persistence were obtained from the DANBIO registry. Information on comorbidities according to the Charlson Comorbidity Index (CCI) was obtained through linkage with the Danish National Patient Register. Kaplan-Meier plots and Cox proportional hazard regression analyses were performed. Percentages of patients achieving relevant clinical responses were calculated. RESULTS: We identified 1,750 patients eligible for analyses. Patients with higher CCI scores had higher disease activity measures at baseline and increased occurrence of depression and/or anxiety. Kaplan-Meier curves showed shorter persistence with treatment for patients with a CCI score ≥2 (log-rank P < 0.001) and for patients with depression and/or anxiety (P = 0.027) compared to patients without comorbidities. In multivariate analysis, a CCI score ≥2 was associated with reduced TNFi persistence compared with patients without comorbidities (hazard ratio 1.72 [95% confidence interval 1.26-2.37]; P = 0.001). A smaller proportion of patients with a CCI score ≥2 achieved European League Against Rheumatism (EULAR) good response (P < 0.001) and EULAR good-or-moderate response (P < 0.001) at 6 months compared with patients without comorbidities. CONCLUSION: The presence of comorbidities was associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates in a cohort of Danish patients with PsA.
Authors: Philip J Mease; Neil A Accortt; Sabrina Rebello; Carol J Etzel; Ryan W Harrison; Girish A Aras; Mahdi M F Gharaibeh; Jeffrey D Greenberg; David H Collier Journal: Rheumatol Int Date: 2019-07-18 Impact factor: 2.631
Authors: Philip J Mease; Chitra Karki; Mei Liu; YouFu Li; Bernice Gershenson; Hua Feng; Peter Hur; Jeffrey D Greenberg Journal: RMD Open Date: 2019-04-24
Authors: Juan D Cañete; Jose Antonio Pinto Tasende; Francisco José Rebollo Laserna; Susana Gómez Castro; Rubén Queiro Journal: Rheumatol Ther Date: 2020-04-08
Authors: Jørgen Guldberg-Møller; Mette Mogensen; Karen Ellegaard; Ali Zavareh; Richard J Wakefield; Ai Lyn Tan; Mikael Boesen; Jamshid Dehmeshki; Olga Kubassova; Lene Dreyer; Marius Henriksen; Lars Erik Kristensen Journal: RMD Open Date: 2022-03
Authors: Kim Wervers; Marijn Vis; Ilja Tchetveriko; Andreas H Gerards; Marc R Kok; Cathelijne W Y Appels; Wiebo L van der Graaff; Johannes H L M van Groenendael; Lindy-Anne Korswagen; Josien J Veris-van Dieren; Johanna M W Hazes; Jolanda J Luime Journal: Arthritis Care Res (Hoboken) Date: 2018-12 Impact factor: 4.794